Aptose Biosciences’ (APTO) “Buy” Rating Reaffirmed at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com began coverage on Aptose Biosciences in a report on Friday. They issued a “hold” rating for the company.

Aptose Biosciences Price Performance

NASDAQ:APTO traded up $0.01 during midday trading on Tuesday, hitting $0.19. The company’s stock had a trading volume of 857,712 shares, compared to its average volume of 288,566. Aptose Biosciences has a fifty-two week low of $0.13 and a fifty-two week high of $2.91. The firm’s 50 day moving average is $0.35 and its 200-day moving average is $0.55. The firm has a market cap of $3.45 million, a P/E ratio of -0.06 and a beta of 1.07.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.